The Moose

Retatrutide or GLP-1 R (30mg) enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss. Its actions on GLP-1 and GIP receptors promote delayed gastric emptying and appetite control, offering a comprehensive approach to obesity research distinct from older GLP-1 agonists.